Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 May;41(5):734–744. doi: 10.1038/bjc.1980.135

Further characterization of a melanoma-specific protein from human urine.

C Bennett, K B Cooke
PMCID: PMC2010305  PMID: 6158965

Abstract

Isolation of a melanoma-specific protein (MSP) from human urine has been achieved using antibody affinity chromatography. MSP migrates as a single homogeneous protein on SDS PAGE and comparison of these data and ultracentrifuge analyses indicates that MSP contains a single polypeptide chain. MSP, however, shows considerable charge heterogeneity on isoelectric focusing. The desialo form, alpha 2 MSP, is found predominantly in patients with advanced metastatic disease, whilst only the sialo form alpha 1 MSP, is obtained from the urine of patients with early-stage disease. MSP does not react with antisera raised to alpha 1 foetoprotein (AFP) or carcinoembryonic antigen (CEA) and hence is immunologically distinct from these other tumour-associated glycoproteins. Antisera raised to MSP do not react with normal skin melanocytes nor with any foetal tissue tested, and hence the origin of MSP remains unresolved.

Full text

PDF
734

Images in this article

740Fig. 1
on p.740
741Fig. 2
on p.741

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Avrameas S., Ternynck T. Biologically active water-insoluble protein polymers. I. Their use for isolation of antigens and antibodies. J Biol Chem. 1967 Apr 10;242(7):1651–1659. [PubMed] [Google Scholar]
  2. Bennett C., Booke K. B. Melanoma specific protein: detection and characterization of a tumour specific protein from melanotic urine. Australas J Dermatol. 1978 Apr;19(1):19–23. doi: 10.1111/j.1440-0960.1978.tb00180.x. [DOI] [PubMed] [Google Scholar]
  3. Bennett C., Copeman P. W. Melanocyte mutation in halo naevus and malignant melanoma? Br J Dermatol. 1979 Apr;100(4):423–426. doi: 10.1111/j.1365-2133.1979.tb01643.x. [DOI] [PubMed] [Google Scholar]
  4. Burtin P., Gendron M. C. A tumor-associated antigen in human nephroblastomas. Proc Natl Acad Sci U S A. 1973 Jul;70(7):2051–2054. doi: 10.1073/pnas.70.7.2051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bystryn J. C., Smalley J. R. Identification and solubilization of iodinated cell surface human melanoma associated antigens. Int J Cancer. 1977 Aug 15;20(2):165–172. doi: 10.1002/ijc.2910200202. [DOI] [PubMed] [Google Scholar]
  6. Carrel S., Theilkaes L. Evidence for a tumour-associated antigen in human malignant melanoma. Nature. 1973 Apr 27;242(5400):609–610. doi: 10.1038/242609a0. [DOI] [PubMed] [Google Scholar]
  7. Elliott P. G., Thurlow B., Needham P. R., Lewis M. G. The specificity of the cytoplasmic antigen in human malignant melanoma. Eur J Cancer. 1973 Aug;9(8):607–610. doi: 10.1016/0014-2964(73)90153-9. [DOI] [PubMed] [Google Scholar]
  8. Gorodilova V. V., Hollinshead A. Melanoma antigens that produce cell-mediated immune responses in melanoma patients: joint U.S.-U.S.S.R. study. Science. 1975 Oct 24;190(4212):391–392. doi: 10.1126/science.1179218. [DOI] [PubMed] [Google Scholar]
  9. Green M. R., Pastewka J. V., Peacock A. C. Differential staining of phosphoproteins on polyacrylamide gels with a cationic carbocyanine dye. Anal Biochem. 1973 Nov;56(1):43–51. doi: 10.1016/0003-2697(73)90167-x. [DOI] [PubMed] [Google Scholar]
  10. Hartree E. F. Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem. 1972 Aug;48(2):422–427. doi: 10.1016/0003-2697(72)90094-2. [DOI] [PubMed] [Google Scholar]
  11. Inman J. K., Dintzis H. M. The derivatization of cross-linked polyacrylamide beads. Controlled introduction of functional groups for the preparation of special-purpose, biochemical adsorbents. Biochemistry. 1969 Oct;8(10):4074–4082. doi: 10.1021/bi00838a026. [DOI] [PubMed] [Google Scholar]
  12. Irie K., Irie R. F., Morton D. L. Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. Cancer Res. 1975 May;35(5):1244–1248. [PubMed] [Google Scholar]
  13. Jehn U. W., Nathanson L., Schwartz R. S., Skinner M. In vitro lymphocyte stimulation by a soluble antigen from malignant melanoma. N Engl J Med. 1970 Aug 13;283(7):329–333. doi: 10.1056/NEJM197008132830702. [DOI] [PubMed] [Google Scholar]
  14. Lewis M. G. Possible immunological factors in human malignant melanoma in Uganda. Lancet. 1967 Oct 28;2(7522):921–922. doi: 10.1016/s0140-6736(67)90236-x. [DOI] [PubMed] [Google Scholar]
  15. McBride C. M., Bowen J. M., Dmochowski L. L. Antinucleolar antibodies in the sera of patients with malignant melanoma. Surg Forum. 1972;23(0):92–93. [PubMed] [Google Scholar]
  16. McCabe R. P., Ferrone S., Pellegrino M. A., Kern D. H., Holmes E. C., Reisfeld R. A. Purification and immunologic evaluation of human melnoma-associated antigens. J Natl Cancer Inst. 1978 Apr;60(4):773–777. doi: 10.1093/jnci/60.4.773. [DOI] [PubMed] [Google Scholar]
  17. Morton D. L., Malmgren R. A., Holmes E. C., Ketcham A. S. Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery. 1968 Jul;64(1):233–240. [PubMed] [Google Scholar]
  18. Phillips B., Roitt I. M. Evidence for transformation of human B lymphocytes by PHA. Nat New Biol. 1973 Feb 21;241(112):254–256. doi: 10.1038/newbio241254a0. [DOI] [PubMed] [Google Scholar]
  19. Ray P. K., Thakur V. S., Sundaram K. Antitumour immunity--1. Differential response of neuraminidase-treated and x-irradiated tumour vaccine. Eur J Cancer. 1975 Jan;11(1):1–8. doi: 10.1016/0014-2964(75)90030-4. [DOI] [PubMed] [Google Scholar]
  20. Righetti P., Drysdale J. W. Isoelectric focusing in polyacrylamide gels. Biochim Biophys Acta. 1971 Apr 27;236(1):17–28. doi: 10.1016/0005-2795(71)90144-9. [DOI] [PubMed] [Google Scholar]
  21. Ruoslahti E., Seppälä M. Studies of carcino-fetal proteins: physical and chemical properties of human alpha-fetoprotein. Int J Cancer. 1971 Mar 15;7(2):218–225. doi: 10.1002/ijc.2910070205. [DOI] [PubMed] [Google Scholar]
  22. SCHEIDEGGER J. J., ROULET H. Applications pratiques de la méthode immuno-électrophorétique; premiers résultats. Praxis. 1955 Jan 27;44(4):73–76. [PubMed] [Google Scholar]
  23. Sharif A., Pico J. L., Choquet C., Rosenfeld C., Bourrillon R. Modifications of lectin binding on human leukemic cells after neuraminidase treatment. Biomedicine. 1978 Apr;29(2):75–79. [PubMed] [Google Scholar]
  24. TOMBS M. P., SOUTER F., MACLAGAN N. F. The spectrophotometric determination of protein at 210 millimicrons. Biochem J. 1959 Sep;73:167–171. doi: 10.1042/bj0730167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. YPHANTIS D. A. EQUILIBRIUM ULTRACENTRIFUGATION OF DILUTE SOLUTIONS. Biochemistry. 1964 Mar;3:297–317. doi: 10.1021/bi00891a003. [DOI] [PubMed] [Google Scholar]
  26. Yon R. J. Chromatography of lipophilic proteins on adsorbents containing mixed hydrophobic and ionic groups. Biochem J. 1972 Feb;126(3):765–767. doi: 10.1042/bj1260765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Zoller M., Matzku S. Antigen and antibody purification by immunoadsorption: elimination of non-biospecifically bound proteins. J Immunol Methods. 1976;11(3-4):287–295. doi: 10.1016/0022-1759(76)90122-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES